New US House Speaker Mike Johnson has opposed marijuana reform
Hard-right conservative Mike Johnson, chosen by House Republicans on Wednesday to be the chamber’s new speaker, has been a staunch opponent of marijuana reform in Congress.
Hard-right conservative Mike Johnson, chosen by House Republicans on Wednesday to be the chamber’s new speaker, has been a staunch opponent of marijuana reform in Congress.
The U.S. Drug Enforcement Administration will “likely” reschedule marijuana, following federal health regulators’ Aug. 29 recommendation, according to a government analysis.
Rescheduling marijuana is positive news in an industry desperate for good news. But make no mistake, it is not enough.
Fourteen Republican federal lawmakers are voicing their opposition to a key federal agency’s recent recommendation that marijuana be rescheduled.
The most significant shift in U.S. marijuana policy is drawing closer, but one major obstacle remains in reform’s way: the Drug Enforcement Administration.
The nation’s largest cannabis multistate operators reported a slowdown in revenue growth in the second quarter, which ended June 30, with efforts to cut costs offset by oversupplied state markets.
The disclosure Wednesday that top Biden administration health officials this week officially recommended marijuana be reclassified from a Schedule 1 substance to Schedule 3 – the same category as Tylenol with codeine – was hailed as the biggest development in MJ policy reform in more than 50 years.
Parties to a cannabis dispute should not rush back into federal court, which has made clear that marijuana cases are not welcome.
A group of suburban Stamford, Connecticut, homeowners who are upset about marijuana legalization is suing to shut down local cannabis sales.
The cannabis industry continues to spend millions of dollars on high-powered lobbyists to sway U.S. senators to pass marijuana reform, but those efforts could be thwarted this fall by a government shutdown that threatens to upend Congress’ legislative calendar.
The Biden administration has yet to provide the U.S. Drug Enforcement Administration a “specific timeline” to complete its review of marijuana’s status under federal law, the agency’s chief told members of Congress on Thursday.
At least five states with medical marijuana programs have shared key data – including the products patients are using and how they are affected – with U.S. health regulators as part of the Biden administration’s review of whether to remove marijuana from the federal government’s list of the most dangerous drugs, MJBizDaily has learned.